SCHEMBL2321735

SCHEMBL2321735

O=C(C1(c2ccc(Cl)cc2)CC1)C1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 13/20 0.59
HDAC4 P56524 1/20 0.56
LMNA P02545 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
TET3 O43151 1/20 0.46
KMT2A Q03164 1/20 0.46
FBXL19 Q6PCT2 1/20 0.46
CXXC5 Q7LFL8 1/20 0.46
KDM2B Q8NHM5 1/20 0.46
CXXC4 Q9H2H0 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554737 0.84 HSD11B1 (0.58) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1
SCHEMBL2097060 0.84 HSD11B1 (0.58) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1
SCHEMBL75310 0.84 TET3 (0.61) HSD11B1HDAC4TET3KMT2AFBXL19
SCHEMBL3406369 0.83 HSD11B1 (0.56) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1
SCHEMBL1975025 0.83 HSD11B1 (0.56) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1
SCHEMBL12020371 0.83 HSD11B1 (0.56) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1
SCHEMBL5007609 0.79 HSD11B1 (0.53) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1
SCHEMBL4445340 0.79 HSD11B1 (0.53) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1
SCHEMBL1335906 0.79 ESR2 (0.48) HSD11B1HDAC4LMNAALDH1A1KMT2A
SCHEMBL1099903 0.78 HDAC4 (0.62) HSD11B1HDAC4LMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103781763-A Amine derivatives as potassium channel blockers BIONOMICS LTD 2014-05-07 CN disclosed
CN-101786948-B Method for preparing 1-(4-chlorphenyl)-2-cyclopropyl-1-acetone JIANGSU AGROCHEM LAB CO LTD 2013-01-30 CN disclosed
EP-2357179-A1 Thiazol-2-yl organic compounds Novartis AG (CH) 2011-08-17 EP disclosed
CN-102131776-A Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof BAYER SCHERING PHARMA AG 2011-07-20 CN disclosed
CN-101786948-A Method for preparing 1-(4-chlorphenyl)-2-cyclopropyl-1-acetone JIANGSU AGROCHEM LAB 2010-07-28 CN disclosed
US-7754746-B2 Organic compounds NOVARTIS AG (CH) 2010-07-13 US disclosed
CN-101374823-A Organic compounds NOVARTIS AG (CH) 2009-02-25 CN disclosed
US-20080319033-A1 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma NOVARTIS AG 2008-12-25 US disclosed
EP-1966175-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2008-09-10 EP disclosed
WO-2007068473-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-06-21 WO disclosed
CN-1215030-C 1,4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents AMERICAN CYANAMID CO (US) 2005-08-17 CN disclosed
CN-1167105-A 1,4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents AMERICAN CYANAMID CO (US) 1997-12-10 CN disclosed
CN-1029123-C Process for preparation of insecticidal cyclopropyl-substituted di(aryl) compounds FMC CORP (US) 1995-06-28 CN disclosed
CN-1069962-A The preparation method of parasiticidal cyclopropyl-replacement two (aromatic base) compound FMC CORP (US) 1993-03-17 CN disclosed
CN-1020091-C Cyclopropyl-substituted di (aryl) insecticidal compositions FMC CORP (US) 1993-03-17 CN disclosed
CN-88101892-A insecticidal cyclopropyl-substituted di (aryl) compounds 1988-11-02 CN disclosed
US-4434182-A Insecticidal substituted-biphenylmethyl oxime ethers FMC CORPORATION (US) 1984-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319033-A1 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma AKT3, PIK3R3, PIK3CD HSD11B1 2776/4885HDAC4 960/4885LMNA 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.